Clinical Trials in Shenzhen, Guangdong
3 recruiting
Showing 1–20 of 22 trials
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled262 locationsNCT07063745
Recruiting
Phase 1Phase 2
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Beijing Biotech60 enrolled1 locationNCT07480213
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Beijing Biotech48 enrolled1 locationNCT07467863
Recruiting
Phase 2
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy
Guangdong Association of Clinical Trials120 enrolled4 locationsNCT07375316
Recruiting
Phase 3
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.416 enrolled69 locationsNCT07047365
Recruiting
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
Peking University Shenzhen Hospital20 enrolled1 locationNCT07374614
Recruiting
Not Applicable
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
Sun Yat-sen University1,124 enrolled23 locationsNCT06524427
Recruiting
Phase 2
A Study of SKB518 in Patients With Lung Cancer
Lung Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.192 enrolled17 locationsNCT07019675
Recruiting
Not Applicable
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
Capital Medical University911 enrolled1 locationNCT07164885
Recruiting
Phase 2
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.270 enrolled25 locationsNCT06496490
Recruiting
Phase 2Phase 3
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled30 locationsNCT06891833
Recruiting
A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
Breast NeoplasmsBreast DiseasesQuality of Life (QOL)+1 more
FangYi3,000 enrolled3 locationsNCT07010939
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Non-small Cell Lung CancerKRAS P.G12C
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Phase 3
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Advanced Non-squamous Non-small-cell Lung Cancer
Allist Pharmaceuticals, Inc.392 enrolled37 locationsNCT06416410
Recruiting
Phase 1Phase 2
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.104 enrolled21 locationsNCT05276726
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns
Metastatic Breast Cancer
Sun Yat-sen University800 enrolled23 locationsNCT06551220
Recruiting
A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
Liver CancerPancreatic CancerGastric Cancer+8 more
Zhujiang Hospital12,000 enrolled50 locationsNCT05638269